Related references
Note: Only part of the references are listed.Considerable differences in vaccine immunogenicities and efficacies related to the diluent used for aluminum hydroxide adjuvant
Lin Lin et al.
CLINICAL AND VACCINE IMMUNOLOGY (2008)
Correlates of vaccine-induced immunity
Stanley A. Plotkin
CLINICAL INFECTIOUS DISEASES (2008)
The antifungal vaccine derived from the recombinant n terminus of Als3p protects mice against the bacterium Staphylococcus aureus
Brad Spellberg et al.
INFECTION AND IMMUNITY (2008)
Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants
Stephanie C. Eisenbarth et al.
NATURE (2008)
Efficacy of the anti-Candida rAls3p-N or rAls1p-N vaccines against disseminated and mucosal candidiasis
BJ Spellberg et al.
JOURNAL OF INFECTIOUS DISEASES (2006)
The anti-Candida albicans vaccine composed of the recombinant N terminus of Als1p reduces fungal burden and improves survival in both immunocompetent and immunocompromised mice
BJ Spellberg et al.
INFECTION AND IMMUNITY (2005)
Type 1 type 2 immunity in infectious diseases
B Spellberg et al.
CLINICAL INFECTIOUS DISEASES (2001)
Th1 and Th2CD4+ T cells provide help for B cell clonal expansion and antibody synthesis in a similar manner in vivo
KM Smith et al.
JOURNAL OF IMMUNOLOGY (2000)
Interleukin-18 (IL-18) and infectious diseases, with special emphasis on diseases induced by intracellular pathogens
I Sugawara
MICROBES AND INFECTION (2000)
Share Paper
